chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Two days after shot woke up with sunburn like rash on face and back.  Was short of breath and dizzy. The rash looked like little blisters on top of bumps on my face, with red rash looking spots on back, legs, and chest. The skin on my face started pealing on my face and it burned and itched. Went to see my Pulmonary Doctor first, than Infectious Disease Doctor than Primary Care. I was treated with steroids, creams and inhalers.  Symptoms would get better than repeat for the first month. Still not feeling like I am ok.  Have two more doctors appts. coming up.
12 hours after administration patient experienced pain down arm into armpit, across back, shoulder, and up neck.  Patient went to ER and was given muscle relaxer and advil and pain went away that evening.
second Moderna shot 42 days later; felt reallylethargic; Very very sore arm; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second Moderna shot 42 days later), LETHARGY (felt reallylethargic) and PAIN IN EXTREMITY (Very very sore arm) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second Moderna shot 42 days later), LETHARGY (felt reallylethargic) and PAIN IN EXTREMITY (Very very sore arm). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second Moderna shot 42 days later), LETHARGY (felt reallylethargic) and PAIN IN EXTREMITY (Very very sore arm) outcome was unknown.            On unknown date, Covid test was performed on patient with Positive results  No concomitant medications were provided.  No treatment medications were provided.     This case was linked to MOD-2021-037367 (Patient Link).
Covid infection >14 days after first eligible dose of vaccination; Covid infection >14 days after first eligible dose of vaccination; This is a literature report. This literature report from a physician reporting same event under the same suspect product for 9 patients. This is one of 9 reports.  Many pregnant persons are receiving messenger RNA (mRNA) coronavirus disease 2019 (Covid-19) vaccines, but data are limited on their safety in pregnancy. Method: From 14Dec2020, to 28Feb2021, authors used data from the Vaccine Adverse Event Reporting System (VAERS), and other data to characterize the initial safety of mRNA Covid-19 vaccines in pregnant persons. Result: A total of 35,691 participants 16 to 54 years of age identified as pregnant. Injection-site pain was reported more frequently among pregnant persons than among nonpregnant women, whereas headache, myalgia, chills, and fever were reported less frequently. Among 3958 participants enrolled 827 had a completed pregnancy, of which 115 (13.9%) resulted in a pregnancy loss and 712 (86.1%) resulted in a live birth (mostly among participants with vaccination in the third trimester). Adverse neonatal outcomes included preterm birth (in 9.4%) and small size for gestational age (in 3.2%); no neonatal deaths were reported. Although not directly comparable, calculated proportions of adverse pregnancy and neonatal outcomes in persons vaccinated against Covid-19 who had a completed pregnancy were similar to incidences reported in studies involving pregnant women that were conducted before the Covid-19 pandemic. Among 221 pregnancy-related adverse events reported to the VAERS, the most frequently reported event was spontaneous abortion (46 cases). Conclusions: Preliminary findings did not show obvious safety signals among pregnant persons who received mRNA Covid-19 vaccines. However, more longitudinal follow-up, including follow-up of large numbers of women vaccinated earlier in pregnancy, is necessary to inform maternal, pregnancy, and infant outcomes.  An adult female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), first dose via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported.  The patient experienced COVID infection more than 14 days after first eligible dose of vaccination on an unspecified date. The mother reported she became pregnant while taking bnt162b2.  The outcome of the event was unknown.  No follow-up attempts are needed. No further information is expected.; Sender's Comments: A causal association between BNT162B2 and the reported events cannot be excluded based on a compatible temporal relation. However, full immunity is only expected 7 days after the second dose.,Linked Report(s) : US-PFIZER INC-2021513072 Pfizer;US-PFIZER INC-2021513093 Pfizer;US-PFIZER INC-2021513094 Pfizer;US-PFIZER INC-2021513095 Pfizer;US-PFIZER INC-2021513097 Pfizer;US-PFIZER INC-2021513098 Pfizer;US-PFIZER INC-2021513099 Pfizer;US-PFIZER INC-2021513096 Pfizer
Hospitalized 01/16/2022-still currently admitted; COVID-19 positive 01/16/2022; fully vaccinated plus booster  Admitting Diagnosis: Acute hypoxemic respiratory failure due to COVID-19  Admitted: 1/16/2022  1:35 PM  ASSESSMENT / PLAN: Patient is a 75 y.o. male with past medical history of type 2 diabetes, hypertension, hyperlipidemia, chronic obstructive pulmonary disease, PVD status post fem-pop bypass who is admitted to the intensive care unit for further management of acute hypoxic respiratory failure and NSTEMI.  New was hypoxic requiring BiPAP with 100% FiO2.  His EKG showed ST depressions and elevated troponins he had further chest pain in the ER.  Case was discussed with interventional cardiology from ER no recommendation for emergent catheterization recommended heparin and transfer to Hospital. Given patient's tenuous respiratory status and requiring BiPAP recommended intubation prior to transfer patient was intubated.  Upon arrival to medical intensive care unit patient was requiring pressors.  And had cool lower extremities.  We ordered stat echocardiogram and placed arterial line.   # Acute hypoxic respiratory failure with bilateral pulmonary infiltrates Pulmonary edema secondary to HF COVID 19 Hx of COPD Possible etiologies include COVID pneumonia, superimposed bacterial pneumonia, pulmonary edema secondary to heart failure.  Some of these, most likely is heart failure due to elevated BNP to 19000, reduced ejection fraction noted on echocardiogram.  Heart failure likely secondary to ischemic event.   Plan:  o Empiric coverage with Unasyn o Blood cultures, sputum culture, bronchoscopy with BAL and associated labs, antigens and cultures o Dexamethasone 6 mg for 10 days o Finish course of remdesivir started at outside hospital o Titrate oxygen to maintain saturation greater than 90% o Albuterol PRN 01/20/22 notes: 1. Acute hypoxic respiratory failure - resolved Possible etiologies include COVID pneumonia, superimposed bacterial pneumonia, pulmonary edema secondary to heart failure.  Some of these, most likely is heart failure due to elevated BNP to 19000, reduced ejection fraction noted on echocardiogram.  Heart failure likely secondary to ischemic event. Patient does have a history of COPD. Patient was successfully extubated to room air on 1/20/22 with no immediate issues. Plan: - COVID 19 - Continue Decadron 6mg qd for 10 d (1/26) - Continue to monitor respiratory status overnight post-extubation - titrate to maintain >90%SpO2 - albuterol PRN - Possible bacterial PNA - unlikely given overall clinical picture showing greater cardiogenic component with little signs of bacterial infection - Cultures NGTD - Unasyn 5 days, last day tomorrow (1/21)
Initial report received from a health care professional on 11 Feb 2010: This patient was vaccinated with FLUVIRIN (batch no: 102149P1), that was stored up to 71 F for up to 13 hours. The patient received 0.5 ml, intramuscular on 09 Feb 2010. No adverse reactions were reported.
Systemic: Allergic: Difficulty Swallowing, Throat Tightness-Mild, Additional Details: Minutes after administeration of vaccine, patient reported that she thinks she is having trouble breathing and it is possible that her throat is swelling shut, she was unsure. Administered bendaryl to patient with a sip of water. After observation for 15-30 minutes, patient said that she feels fine. Patient said that she also has asthma which may have contributed to her symptom(s).
RN drew 0.4ml from bottom of one vial (037C21A) and 0.1ml from another adjacent vial (likely 024C21A) into a single syringe; This spontaneous case was reported by a health care professional and describes the occurrence of PRODUCT ADMINISTRATION ERROR (RN drew 0.4ml from bottom of one vial (037C21A) and 0.1ml from another adjacent vial (likely 024C21A) into a single syringe) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037C21A, 024C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Oct-2021 at 3:00 PM, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Oct-2021, the patient experienced PRODUCT ADMINISTRATION ERROR (RN drew 0.4ml from bottom of one vial (037C21A) and 0.1ml from another adjacent vial (likely 024C21A) into a single syringe). On 28-Oct-2021, PRODUCT ADMINISTRATION ERROR (RN drew 0.4ml from bottom of one vial (037C21A) and 0.1ml from another adjacent vial (likely 024C21A) into a single syringe) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication information was provided. No treatment information was provided.
patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided. No treatment medications were provided.
Patient experienced redness and swelling at site of injection and directly adjacent to it on the arm. She also mentioned feeling "flu-like" symptoms (more severe than her 1st dose), but has gone away. She was complaining of a spreading rash.
Phone call received from pt. on 5/2/05 to report sorenes of left arm.  Reports arm feels weak and has difficulty using left arm. Reports feeling a "burning" and "freezing" at time of injection of TD.  Client seen by physician on 5/2/05 and reports she was started on "steroid" and "ibuprofen".  Reports on 5/10/05 she is much improved.
A little over 24 hours after my second dose I started to feel muscle aches, a fever of 102.4, headache, chills, fatigue, diarrhea, sweating, injection site pain, stomach pain and upset.  I have been taking Tylenol and Ibuprofen to help with the aches and pains and NyQuil at night to help with fever and aches. It is helpful. I have been eating a BRAT diet and drinking a lot of vitamin water with 0 sugars.
Emesis, hives, facial/eye swelling, wheezing.  All symptoms within 10 minutes of reaction (by 3:50 PM). Benadryl (po), albuterol nebulizer given, transported by MEDIC 5 to ED for Epinephrine and monitoring
Day after: aches, headache, fever. One week later extreme tinnitus in left ear. Daily headaches.
After receiving my first vaccine on 4/13/21, I had a small asthma attack after about 20 minutes that went away quickly. After my second dose, I started feeling out of control of my muscles almost immediately. I also noticed the injection site was bleeding more than the first shot. 30 minutes later, the shaking became extensive and uncontrollable. I returned to clinic and the paramedics told me I was having an anxiety attack. The shaking continued on and at about 4:00pm I felt that my throat was puffing up. I went to the hospital and they put me on a variety of medications (Benadryl, Pepcid, and methylprednisolone). I felt better soon after. The next morning I have a sore throat, feel feverish and have a headache.
This spontaneous report was received from a registered nurse and refers to a multiple, unspecified patients of an unknown age and gender. There was no information about the patients' concurrent conditions, concomitant therapies or medical history provided. On an unspecified dates, the patients were vaccinated with improperly stored doses of M-M-R II injection, lot# M015931 with an expiration date 30-MAR-2018, lot# M027637 with an expiration date 02-JUN-2018 and lot # M011667 with an expiration date 08-MAR-2018 for prophylaxis (dose and route of administration were not reported). Administered doses of M-M-R II experienced the temperature excursion between 46 and 77 degrees Fahrenheit for 2 hours and 15 minutes and between 27 and 36 degrees Fahrenheit for an undetermined length of time. No adverse effects were reported. A digital data logger was involved. There were more than 10 previous multiple excursions. Product quality complaint (PQC) was not reported. This is one of two reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1702USA004706.
Patient returned to clinic on 08/25/2008 complaining of tenderness on the right upper arm.  The wound was 2 x 3 inches, round, warm, red.
WEAKNESS; FATIGUE; MUSCLE CRAMPS ON LEFT AND  RIGHT SIDE LOWER BACK; MUSCLE ACHES ON LEFT AND  RIGHT SIDE LOWER BACK/MUSCLE PAIN; DIARRHEA; LOST TASTE BUDS; DIZZINESS; HIGH FEVER; PAIN AT INJECTION SITE; BURNING AT INJECTION SITE; SWELLING AT INJECTION SITE; HEADACHE/ HEAD HURTING; This spontaneous report received from a patient concerned a 41 year old male. The patient's height, and weight were not reported. The patient's concurrent conditions included sinus issues, and other pre-existing medical conditions included the patient is unaware of any known allergies. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 205A21A, and expiry: UNKNOWN) dose was not reported, administered on 08-APR-2021 10:45:00 for prophylactic vaccination. No concomitant medications were reported. On 08-APR-2021, the subject experienced dizziness. On 08-APR-2021, the subject experienced high fever. On 08-APR-2021, the subject experienced headache/ head hurting. On 08-APR-2021, the subject experienced pain at injection site. On 08-APR-2021, the subject experienced burning at injection site. On 08-APR-2021, the subject experienced swelling at injection site. Laboratory data included: Body temperature (NR: not provided) 98.9 F. On 10-APR-2021, the subject experienced diarrhea. On 10-APR-2021, the subject experienced lost taste buds. On 11-APR-2021, the subject experienced muscle cramps on left and right side lower back. On 11-APR-2021, the subject experienced muscle aches on left and right side lower back/muscle pain. On an unspecified date, the subject experienced weakness, and fatigue. Treatment medications (dates unspecified) included: ibuprofen. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from lost taste buds on 10-APR-2021, and high fever, and headache/ head hurting on 09-APR-2021, and the outcome of muscle aches on left and right side lower back/muscle pain, diarrhea, dizziness, fatigue, weakness, muscle cramps on left and right side lower back, pain at injection site, burning at injection site and swelling at injection site was not reported. This report was non-serious.
Moderna COVID -19 Vaccine EUA - arm still sore in the spot of the shot. how long does it last.  I didn't notice the pain 4 days past the vaccination, but suddenly I do? i honestly thought it would have gone away by now..
It was reported that an adult female patient received an administration of Fluzone SV '01-'02 in left deltoid lot # UO701AA on Wednesday 11/07/01 The patient stated that she noticed a change on 11/14/01 at 11am with a loud roaring and ringing in left ear. She called her doctor who evaluated her and couldn't find or see anything wrong. Audiot test showed hearing loss in the left ear. Her right ear has perfect hearing.  He suggested she starts Prednisone. She did not chose to do this. She received some information from a friend which refers to reports of "labyrinth" temporary problems which have resolved. She is going to call her doctor back now to tell him her problem are "vaccine related."
pain arm; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (pain arm) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 01M20A) for COVID-19.     No Medical History information was reported.    On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Feb-2021, the patient experienced PAIN IN EXTREMITY (pain arm). The patient was treated with IBUPROFEN (ADVIL 12 HOUR) at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (pain arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment information included, Advil.   Reporter did not allow further contact
Less than 50 pox per father, no fever. On torso, neck, head started yesterday evening (11/22/11).
Information has been received from a registered nurse concerning a female patient who in 2003 was vaccinated with a complete series doses of RECOMBIVAX HB (Lot# not reported) (manufacturer unknown). The nurse stated that a titer after vaccination in 2003 was performed, which was positive; on 14-DEC-2010 another hepatitis B was done and was negative. It was also reported that the patient had a hepatitis B exposure recently. At the time of the report the patient had not recovered. It was unspecified if the patient sought medical attention. Additional information has been requested.
After 2 minutes from time of injection, tongue swelled, chest tightness, difficulty breathing, hives. Treated in Emergency Dept. with Epinephrine 0.3sq 02 and Prednisone 20mg PO.
Patient reported stating feeling nauseous, lightheadedness, paleness, dizziness, and had trouble seeing to observation nurse, at 1116 AM. Vaccination nurse went to notify charge nurse on patient status. Vital signs included T 96.1, o2 99, RR 16, B/P 106/76, and HR 52 at 1116 AM. Supervisor on site notified the doctor via telephone at 1144 AM. Reassessed at 1126 AM second set of vital signs includes T 96.1, o2 98, RR 18, B/P 94/74, and HR 77.Currently patient does not display any s/s of distress or discomfort third set of vital signs includes T 97.0, o2 98, RR 18, B/P 116/86, and HR 78. As per MD patient is stable and can go home, clear to leave observation area. Patient instructed to contact HCP and/or go to ER if displays s/s.
Felt Dizzy, plus rapid heartbeat, tightening of throat, muscle soreness and fatigue.  Symptoms occurred 45 minutes after injection.    Symptoms lasted  about 90 minutes.   Did lay down for 15 minutes which helped.
Tongue was swollen; Temples starting hurting and pounding; Itching all over (not all once but it moved to different areas, even in my ears); This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itching all over (not all once but it moved to different areas, even in my ears)), SWOLLEN TONGUE (Tongue was swollen) and HEADACHE (Temples starting hurting and pounding) in a 53-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040B21A) for COVID-19 vaccination.     Concurrent medical conditions included Autoimmune disorder (Patient reported that the tongue will swell when the patient have flare-ups of auto-immune disease-A form of Lupus and Lichen planus.). Concomitant products included AMLODIPINE, TRIAMCINOLONE and VITAMIN D [VITAMIN D NOS] for an unknown indication.    On 08-Apr-2021 at 6:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Apr-2021, the patient experienced PRURITUS (Itching all over (not all once but it moved to different areas, even in my ears)). On 09-Apr-2021 at 7:15 AM, the patient experienced HEADACHE (Temples starting hurting and pounding). On an unknown date, the patient experienced SWOLLEN TONGUE (Tongue was swollen). At the time of the report, PRURITUS (Itching all over (not all once but it moved to different areas, even in my ears)) had resolved and SWOLLEN TONGUE (Tongue was swollen) and HEADACHE (Temples starting hurting and pounding) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.  Treatment information not provided.
Two spots that looked like a vampire bite showed up on my neck. Never had this before. Chunks of 'something' came out later. Spotting - post menopausal. Hadn't had a period in years. All of a sudden, I'm having spotting. Had an IUD to stop the bleeding 5 years ago. I had not had spotting or bleeding until this shot. Dizziness Diarrhea, Nausea High Fatigue Headache
After administrating Meningococcal vaccine patient fell foward off of examining table onto the floor and appeared to have seizure-like movements for about 3 seconds. Sat on floor for a few minutes and was asked questions as to alertness which she was so was assisted was assisted to couch to lay down and was given some juice. Mother had given her some Tylenol she complained of her right ear hurting. Doctor was notified and examined. After about 30 minutes patient stated that she was feeling better and was able to go home.